Tourmaline Bio Inc
NASDAQ:TRML
Tourmaline Bio Inc
NASDAQ:TRML
Price:
15.01 USD
-1.57%
Market Closed
Updated:
May 16, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of TRML.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TRML
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
TRML Competitors Multiples
Tourmaline Bio Inc Competitors
Tourmaline Bio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Tourmaline Bio Inc
NASDAQ:TRML
|
599.6m USD | 0 | -14.2 | -8.7 | -8.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.3B USD | 5.3 | 60.2 | 13.1 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.9B USD | 5.7 | 44.9 | 18.9 | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD | 11.5 | 31.3 | 25.3 | 26.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.7B USD | 8.1 | 27.7 | 22.4 | 24.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
138.6B AUD | 6.6 | 37.6 | 22.6 | 28.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 3.1 | 174.7 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.9B USD | 9.9 | -8.5 | -9.4 | -8.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.5B USD | 3.5 | 28.7 | 14.6 | 18.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.7 | 45.7 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
